Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 307 followers
Latest posts
Last updated 2 days ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
2 days ago
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically...
Invitation: Roche virtual late-stage oncology pipeline update at ASCO 2024
10 days ago
We are pleased to invite investors and analysts to participate in our...
Reminder: Roche Diagnostics Day 2024
10 days ago
The Roche Investor Relations team would like to invite you to the...
Roche’s OCREVUS subcutaneous injection receives EU CHMP positive opinion for relapsing and primary progressive multiple sclerosis
19 days ago
If approved, OCREVUS subcutaneous (SC) would be the first and only twice-a-year...
CHMP recommends EU approval of Roche’s Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancer
22 days ago
If approved, Alecensa will be the first and only ALK inhibitor approved...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
24 days ago
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in...
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
29 days ago
Approval based on Phase III ALINA study showing Alecensa reduced the risk...
Reminder: Invitation to Roche’s First Quarter Sales 2024 Presentation
about 1 month ago
Roche will publish its Sales Results for the 1st Quarter 2024 prior...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
about 1 month ago
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall...
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
about 1 month ago
The Elecsys® pTau217 plasma biomarker test is being developed as part of...
Invitation: Roche Diagnostics Investor Day 2024
about 1 month ago
The Roche Investor Relations team would like to invite you to the...
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
about 1 month ago
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood...